ANDA 84349, held by Viatris. Phenytoin Sodium.
As of Nov 16, 2026, ANDA 84349 (Dilantin), held by Viatris, was first approved by FDA on Aug 27, 1976, with 45 approved supplements and 0 published complete response letters.
DILANTIN is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 27, 1976 | Original application | Approved | None posted |
| Dilantin30MG EXTENDED · capsule;oral | Phenytoin Sodium | RxReference drug |
| Dilantin100MG EXTENDED · capsule;oral | Phenytoin Sodium | RxReference drug |
| Sep 7, 2022 | Supplement 88Labeling · Standard review | Approved | |
| Oct 22, 2021 | Supplement 87Labeling · Standard review | Approved | |
| Aug 7, 2020 | Supplement 86Labeling · Standard review | Approved | |
| Dec 3, 2018 | Supplement 85Labeling · Standard review | Approved | |
| Dec 22, 2017 | Supplement 81Labeling · Standard review | Approved | |
| Dec 22, 2017 | Supplement 82Labeling · Standard review | Approved | |
| Dec 22, 2017 | Supplement 84Labeling · Standard review | Approved | |
| Feb 1, 2017 | Supplement 75Labeling · Standard review | Approved | None posted |
| Feb 1, 2017 | Supplement 77Labeling · Standard review | Approved | None posted |
| Feb 1, 2017 | Supplement 78Labeling · Standard review | Approved | None posted |
| Feb 1, 2017 | Supplement 79Labeling · Standard review | Approved | None posted |
| Feb 1, 2017 | Supplement 80Labeling · Standard review | Approved | |
| Apr 16, 2015 | Supplement 74Labeling · Standard review | Approved | |
| Jul 3, 2014 | Supplement 73Labeling · Standard review | Approved | |
| Feb 27, 2014 | Supplement 62Labeling | Approved | |
| Feb 27, 2014 | Supplement 72Labeling · Standard review | Approved | |
| Dec 26, 2013 | Supplement 71Labeling · Standard review | Approved | None posted |
| Aug 6, 2013 | Supplement 70Labeling · Standard review | Approved | |
| Nov 27, 2012 | Supplement 67Labeling | Approved | |
| Apr 8, 2011 | Supplement 64REMS | Approved | |
| Jul 9, 2009 | Supplement 56Labeling | Approved | None posted |
| May 6, 2009 | Supplement 60Labeling | Approved | |
| Aug 8, 2007 | Supplement 45Manufacturing | Approved | |
| Aug 8, 2007 | Supplement 41Labeling | Approved | None posted |
| Dec 9, 2003 | Supplement 40Labeling | Approved | None posted |
| Mar 25, 1998 | Supplement 38Manufacturing | Approved | None posted |
| Mar 25, 1998 | Supplement 37Manufacturing | Approved | None posted |
| Apr 3, 1997 | Supplement 34Manufacturing | Approved | None posted |
| Feb 12, 1997 | Supplement 31Manufacturing | Approved | None posted |
| Feb 11, 1997 | Supplement 33Manufacturing | Approved | None posted |
| Sep 19, 1996 | Supplement 35Manufacturing | Approved | None posted |
| Nov 15, 1993 | Supplement 30Manufacturing | Approved | None posted |
| Mar 22, 1990 | Supplement 26Bioequivalence | Approved | None posted |
| Aug 25, 1988 | Supplement 24Manufacturing | Approved | None posted |
| Aug 25, 1988 | Supplement 23Manufacturing | Approved | None posted |
| Oct 15, 1986 | Supplement 19Manufacturing | Approved | None posted |
| Feb 11, 1986 | Supplement 20Manufacturing | Approved | None posted |
| Jun 14, 1984 | Supplement 13Manufacturing | Approved | None posted |
| Apr 9, 1984 | Supplement 12Manufacturing | Approved | None posted |
| Apr 9, 1984 | Supplement 11Manufacturing | Approved | None posted |
| Apr 9, 1984 | Supplement 9Manufacturing | Approved | None posted |
| Jun 2, 1982 | Supplement 7Manufacturing | Approved | None posted |
| Jun 2, 1982 | Supplement 6Manufacturing | Approved | None posted |
| May 27, 1982 | Supplement 5Manufacturing | Approved | None posted |
| May 18, 1982 | Supplement 8Manufacturing | Approved | None posted |
| Aug 27, 1976 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters